First, while mutations that activate MEK/ERK signaling are prevalent in chemorelapse NB (Eleveld et al., 2015; Padovan-Merhar et al., 2016), most appear to be SHP2 dependent (e.g., ALK mutations, NF1 loss) and not RAF/RAS mutated. This evidence concerns the gene MAP2K7 and neuroblastoma.